Antigen-capturing and mannose receptor-targeting nanomedicine, preparation method, and application thereof

By preparing nanodrugs targeted by antigen capture and mannose receptors, the ineffectiveness of thermal ablation therapy combined with immune checkpoint blockade treatment was solved, and the tumor suppression and long-term survival rates were improved, especially in the treatment of hepatocellular carcinoma.

CN115463224BActive Publication Date: 2025-09-02THE SECOND AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY
2 Cites 0 Cited by

Patent Information

Application Number
CN202210929412.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-08-03
Publication Date
2025-09-02
Estimated Expiration
2042-08-03

AI Technical Summary

Technical Problem

Existing thermal ablation therapy combined with immune checkpoint blockade may experience ineffective tumor suppression in hepatocellular carcinoma treatment, and distal tumors can still grow and reproduce.

Method used

Nanopharmaceuticals targeted by antigen capture and mannose receptors were prepared, and FTO inhibitors were loaded in mesoporous polydopamine nanoparticles. Mannose was used as a ligand to target dendritic cells to improve tumor antigen uptake efficiency, and RNA m6A methylation level was increased through FTO inhibitors, promoting dendritic cell maturation and activate anti-tumor immune response.

Benefits of technology

Through the application of nanodrugs, the growth of distal tumors is significantly inhibited, the long-term survival rate is improved, and the anti-tumor effect of immune checkpoint blocking treatment is enhanced.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

This invention belongs to the field of biomedicine and specifically relates to an antigen-capturing and mannose receptor-targeting nanodrug, its preparation method, and its application. This nanodrug can capture tumor-associated antigens released after thermal ablation of cancer cells and, in combination with an FTO inhibitor, deliver them to tumor-infiltrating dendritic cells. After thermal ablation, the synergistic effect of the nanodrug and immune checkpoint blockade therapy inhibits distal tumor growth and improves long-term survival.
Need to check novelty before this filing date? Find Prior Art